https://t.co/8QFvLfIDVg Our group at @amritafbd is glad to publish validation and first Indian experience with NGS based MRD testing in B-ALL in e_JHaem journal @moushumi_surya @NitinJainMD @Dr Nupur das @e_JHaem

🚨 CAPItello-290 | 1L mTNBC Can AKT inhibition improve outcomes in first-line metastatic TNBC? Here is the data. 🧪 Trial essentials Global phase III 1L metastatic or inoperable locally advanced TNBC ~31% had PIK3CA / AKT1 / PTEN alterations 💊 Arms Capivasertib + paclitaxel

DUMB INDIAN CUSTOMERS are always SCAMMED... "Jago Grahak Jago"

If you're having a bad day, here's a Panda playing in the snow

🚨 FDA APPROVAL | EGFR-mutant NSCLC Rybrevant Faspro (amivantamab + hyaluronidase-lpuj) is now FDA-approved for first-line use with Lazcluze (lazertinib) 🇺🇸💊 🧬 Who is this for? Treatment-naive advanced EGFR exon 19 del / L858R NSCLC ⏱️ What changes clinically? • IV

Came across this video from @TajMahalMumbai welcoming #Messi𓃵

HAT-TRICK IN HELL 🏆🏆🏆 Mathieu van der Poel reigned supreme once again in 2025 — three straight wins at Paris–Roubaix! 🔥

🎉🎉 Happy to share our new paper, out now in @BrJHaem GVHD free/relapse free survival (GRFS) is a clinically important endpoint in alloBMT, especially for young adults We used a @CIBMTR dataset to analyse the impact of GvHD prophylaxis on GRFS in this population

#SABCS25 Day 3 highlights by @OncBrothers ⤵️ Ambre Viktoria1 Patina

PI3K I go to summary for clinics ⤵️ #SABCS25

🧠💊 #SABCS25 Can we delay brain mets in HR+/HER2+ MBC? #PATINA shows that adding palbociclib to anti-HER2 + endocrine therapy reduces CNS events 📉 🧬 Trial: PATINA phase III 👥 HR+/HER2+ metastatic breast cancer ⚖️ Arms ➕ ➡️ Palbociclib + trastuzumab + pertuzumab + ET ➡️

If you paying $500 for a racing shoe, you better be running so fast the watch can’t even catch you 😭 That $500 one? Not possible for me. I can’t. BUT I’m not judging nobody… if you got it, enjoy. Shoes help… but they not magic. What you racing next and what you wearing?

Phu quoc My home for next 3 days

Gene Solutions Satellite Symposium brought together distinguished oncology experts from across the Asia-Pacific region, delivering clinically relevant insights on early cancer detection, individualized treatment planning, and real-time molecular monitoring. Seeing our team

😀 हमेशा *ट्रेनों में खड़े होकर* सफर करने वाले लोग भी बहाना बना रहे हैं कि....... आपके यहां *शादी* में नहीं आ पाऊंगा *मेरी फ्लाइट ✈️✈️केंसल हो गई है !*😀😀😀😀 #Indigo

Congratulations @samdoc_mamc and Sachin Sarcoma Society #Sarcoma

🚨 One HPV dose works as well as two New NEJM ESCUDDO trial in 20,330 girls shows something remarkable 😮 A single dose of either bivalent or nonavalent HPV vaccine was noninferior to two doses for preventing persistent HPV16/18 infection up to 60 months 🎯 🧪 Trial design 👧

🚨 St Gallen 2025: Evidence-backed upgrades in early breast cancer A consensus now aligned with KEYNOTE-522, TAILORx, SOUND, INSEMA, KATHERINE and OlympiA. 1) Genetics & Prevention 🧬 BRCA1/2, PALB2 → strong support for contralateral risk-reducing surgery. 📌 Evidence:

Here is the result of action #Singapore

After adjuvant pembro, what do guidelines really say? 👀 #GlobalForum25 🔥 ESMO Still no clear rule. Sequencing ICIs after long disease-free intervals is basically unknown territory. 🚫 EAU If recurrence happens during or within 6 months of adjuvant pembro, avoid ICI or ICI